Pharmacological Inhibition of CETP (Cholestery Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease

OBJECTIVE: Plasma total HDL (high-density lipoprotein) is a heterogeneous mix of many protein-based subspecies whose functions and associations with coronary heart disease vary. We hypothesize that increasing HDL by CETP (cholesteryl ester transfer protein) inhibition failed to reduce cardiovascular...

Full description

Bibliographic Details
Main Authors:	Carvajal-Gonzalez, S. (Author), Dullea, R. (Author), Furtado, J.D (Author), Nicholls, S.J (Author), Ruotolo, G. (Author), Sacks, F.M (Author)
Format:	Article
Language:	English
Published:	Lippincott Williams and Wilkins 2022
Subjects:	aged Aged Antagonists & inhibitors Anticholesteremic Agents apolipoprotein C3 Apolipoprotein C-III Apolipoproteins atorvastatin Atorvastatin benzodiazepine derivative Benzodiazepines blood CETP protein, human cholesterol ester transfer protein Cholesterol ester transfer proteins Cholesterol Ester Transfer Proteins clinical trial complication controlled study coronary artery disease Coronary Disease evacetrapib ezetimibe Ezetimibe female Female HDL Heart Disease Risk Factors Heart diseases high density lipoprotein human Humans Hydroxymethylglutaryl-CoA reductase inhibitors hyperlipidemia Hyperlipidemias hypocholesterolemic agent Lipoproteins Lipoproteins, HDL male Male middle aged Middle Aged multicenter study phase 3 clinical trial randomized controlled trial
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Pharmacological Inhibition of CETP (Cholestery Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease

Internet

Similar Items